Deutsch English Français

Contact

EP2307389

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2307389

EP2307389 - DIBENZOTHIAZEPINE DERIVATIVE AND USE THEREOF [Right-click to bookmark this link]
Former [2011/15]	DIBENZOTHIAZEPINE DERIVATIVES AND USE THEREOF
	[2012/39]
Status	No opposition filed within time limit Status updated on 29.11.2013 Database last updated on 05.10.2024
Most recent event Tooltip	24.01.2014	Change - lapse in a contracting state State(s) deleted from list of lapses: CY	published on 26.02.2014 [2014/09]
Applicant(s)	For all designated states AstraZeneca AB 151 85 Södertälje / SE
	[2011/15]
Inventor(s)	01 / BROWN, Dean AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	02 / DAMEWOOD, James R. AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	03 / EDWARDS, Phil c/o AstraZeneca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437, Wilmington Delaware 19850-5437 / US
	04 / HULSIZER, James c/o Astrazeneca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US
	05 / MUIR, James Campbell AstraZeneca Charter Way Macclesfield Cheshire SK10 2NA / GB
	06 / PIERSON JR., M. Edward AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	07 / SHENVI, Ashokkumar Bhikkappa AstraZeneca R&D Wilmington c/o Astrazeneca Intellectual Property 1800 Concord Pike P.O. Box 15437, Wilmington Delaware 19850-5437 / US
	08 / WESOLOWSKI, Steven AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	09 / WIDZOWSKI, Dan AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	10 / WOOD, Michael AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington DE 19850-5437 / US
	[2013/04]
Former [2011/15]	01 / BROWN, Dean AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	02 / DAMEWOOD, James R. AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	03 / EDWARDS, Phil c/o AstraZeneca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	04 / HULSIZER, James c/o Astrazeneca Intellectual Property AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington, Delaware 19850-5437 / US
	05 / MUIR, James Campbell AstraZeneca Charter Way Macclesfield Cheshire SK10 2NA / GB
	06 / PIERSON JR., M. Edward AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	07 / SHENVI, Ashokkumar Bhikkappa AstraZeneca R&D Wilmington c/o Astrazeneca Intellectual Property 1800 Concord Pike P.O. Box 15437 Wilmington Delaware 19850-5437 / US
	08 / WESOLOWSKI, Steven AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	09 / WIDZOWSKI, Dan AstraZeneca R&D Boston 35 Gatehouse Drive Waltham, MA 02451 / US
	10 / WOOD, Michael AstraZeneca R&D Wilmington 1800 Concord Pike P.O. Box 15437 Wilmington DE 19850-5437 / US
Representative(s)	Curran, Clair, et al Ropes & Gray International LLP 5 New Street Square London EC4A 3BF / GB
	[2013/39]
Former [2011/15]	Steinrud, Henrik, et al AstraZeneca AB Global Intellectual Property S-151 85 Södertälje / SE
Application number, filing date	09766953.5	18.06.2009
	[2011/15]
	WO2009SE50763
Priority number, date	US20080074417P	20.06.2008 Original published format: US 74417 P
	[2011/15]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2009154563
	Date:	23.12.2009
	Language:	EN
	[2009/52]
	Type:	A1 Application with search report
	No.:	EP2307389
	Date:	13.04.2011
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 23.12.2009 takes the place of the publication of the European patent application.
	[2011/15]
	Type:	B1 Patent specification
	No.:	EP2307389
	Date:	23.01.2013
	Language:	EN
	[2013/04]
Search report(s)	International search report - published on:	SE	23.12.2009
	(Supplementary) European search report - dispatched on:	EP	13.03.2012
	Supplementary international search report - requested on:	RU	18.01.2010
Classification	IPC:	C07D281/16, A61K31/554, A61P25/18, A61P25/24, A61P25/22	[2012/15]
	CPC:	C07D417/04 (EP,US); A61K31/554 (EP,US); A61P25/00 (EP); A61P25/18 (EP); A61P25/22 (EP); A61P25/24 (EP); (+) C07D281/16 (EP,US) (-)
	Former IPC [2011/15]	C07D281/16, A61K31/554, A61P25/18, A61P25/24
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2011/15]
Extension states	AL	20.01.2011
	BA	20.01.2011
	RS	20.01.2011
Title	German:	DIBENZOTHIAZEPINDERIVAT UND ANWENDUNG DAVON	[2012/39]
	English:	DIBENZOTHIAZEPINE DERIVATIVE AND USE THEREOF	[2012/39]
	French:	DÉRIVÉ DE DIBENZOTHIAZÉPINE ET SON UTILISATION	[2012/39]
	Former [2011/15]	DIBENZOTHIAZEPINDERIVATE UND ANWENDUNG DAVON
	Former [2011/15]	DIBENZOTHIAZEPINE DERIVATIVES AND USE THEREOF
	Former [2011/15]	DÉRIVÉS DE DIBENZOTHIAZÉPINE ET LEUR UTILISATION
Entry into regional phase	20.01.2011	National basic fee paid
	20.01.2011	Search fee paid
	20.01.2011	Designation fee(s) paid
	18.01.2011	Examination fee paid
Examination procedure	18.01.2011	Examination requested [2011/15]
	11.03.2011	Amendment by applicant (claims and/or description)
	22.03.2012	Despatch of a communication from the examining division (Time limit: M04)
	20.07.2012	Reply to a communication from the examining division
	03.09.2012	Communication of intention to grant the patent
	13.12.2012	Fee for grant paid
	13.12.2012	Fee for publishing/printing paid
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.03.2012
Opposition(s)	24.10.2013	No opposition filed within time limit [2014/01]
Fees paid	Renewal fee
	30.06.2011	Renewal fee patent year 03
	02.07.2012	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	deleted
	[2014/09]
Former [2014/01]	CY	23.01.2013
Former [2013/52]	CY	23.01.2013
	NO	23.04.2013
Former [2013/33]	NO	23.04.2013
Documents cited:	Search	[YD]CH422793 (WANDER AG DR A [CH]) [YD] 1-15 * page 2, lines 79-82; claim - *;
		[XY]FR1508536 (AMERICAN CYANAMID CO) [X] 1,8-15 * page 1; résumé * [Y] 2-7;
		[Y]US3539573 (SCHMUTZ JEAN, et al) [Y] 1-15* column 2, lines 36-39; claim - *;
		[XY]EP0447857 (HOKURIKU PHARMACEUTICAL [JP]) [X] 1,8-15 * page 7, lines 35-39; claim - * [Y] 2-7;
		[XY]WO2005063254 (ACADIA PHARM INC [US], et al) [X] 1,8-15 * abstract * [Y] 2-7;
		[XY]US2006063754 (EDGAR DALE M [US], et al) [X] 1,8-15 * paragraphs [0243] - [0248]; claim - * [Y] 2-7
	International search	[A]GB980853 (WANDER S A A);
		[A]SU457220 ;
		[A]RU2006126720
	International search	[X]US3962248 (SCHNEIDER JOSEF);
		[X]EP0447857 (HOKURIKU PHARMACEUTICAL [JP]);
		[X]WO9618621 (ALLELIX BIOPHARMA [CA]);
		[X]WO2005063254 (ACADIA PHARM INC [US], et al);
		[X]US2006063754 (EDGAR DALE M [US], et al);
		[A]WO2006073360 (ASTRAZENECA AB [SE], et al);
		[A]US2006217366 (DAVIS PATRICIA C [US], et al);
		[X]WO2006107948 (ACADIA PHARM INC [US], et al);
		[X]WO2007053618 (ACADIA PHARM INC [US], et al)
	by applicant	NL293210
		CH422793
		FR1508536
		US3539573
		EP0447857
		US2006063754
		US7491715
		US7517871
		- "Behavioral Approach to Nondyskinetic Antagonists: Identification of Seroquel", J. MED. CHEM., (2001), vol. 44, pages 372 - 380
		- LAZARENO, METHODS IN MOLECULAR BIOLOGY, (1999), vol. 106, pages 231 - 245
		- DE BACKER ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1993), vol. 197, no. 3, page 1601

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p